Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643385 | 0.89 | L3MBTL1 (0.56) | L3MBTL1SIGMAR1PRKAA2MCHR1OGA | |
| Hydrochloric Acid SCHEMBL4209320 | 0.88 | L3MBTL1 (0.55) | L3MBTL1SIGMAR1PRKAA2MCHR1OGA | |
| SCHEMBL7105933 | 0.84 | LMNA (0.63) | SIGMAR1PRKAA2OGAUSP30 | |
| SCHEMBL13951400 | 0.83 | SIGMAR1 (0.69) | L3MBTL1SIGMAR1 | |
| SCHEMBL3640922 | 0.83 | SIGMAR1 (0.58) | L3MBTL1SIGMAR1PRKAA2USP30 | |
| SCHEMBL3674402 | 0.83 | SIGMAR1 (0.61) | L3MBTL1SIGMAR1PRKAA2MCHR1OGA | |
| SCHEMBL3641995 | 0.83 | CCR5 (0.67) | SIGMAR1USP30 | |
| SCHEMBL3638459 | 0.83 | OGA (0.55) | L3MBTL1SIGMAR1PRKAA2MCHR1OGA | |
| SCHEMBL3814195 | 0.82 | KCNA3 (0.64) | SIGMAR1 | |
| SCHEMBL4217001 | 0.82 | SIGMAR1 (0.57) | L3MBTL1SIGMAR1PRKAA2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173715-A2 | USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY | Euroscreen S.A. (BE) | 2010-04-14 | — | — | EP | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009010478-A2 | USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | L3MBTL1 4857/4885SIGMAR1 129/4885PRKAA2 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.